GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Acorda Therapeutics, Inc. (ACOR) [hlAlert]

Rating:
Buy ACOR
down 0.03 %

Acorda Therapeutics, Inc. (ACOR) rated Buy with price target $47 by Stifel

Posted on: Tuesday,  Aug 19, 2014  12:00 AM ET by Stifel

Stifel rated Buy Acorda Therapeutics, Inc. (NASDAQ: ACOR) on 08/19/2014, when the stock price was $31.70. Since
then, Acorda Therapeutics, Inc. has lost 0.03% as of 01/26/2016's recent price of $31.69.
If you would have followed this Stifel's recommendation on ACOR, you would have lost 0.03% of your investment in 525 days.

Acorda Therapeutics is commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the central nervous system. Acorda currently markets Zanaflex Capsules for the management of spasticity. The Company's lead product candidate, Fampridine-SR, for the improvement of walking ability in persons with multiple sclerosis. It develops therapies that restore neurological function to people with spinal cord injury, multiple sclerosis and related conditions of the nervous system.

Stifel
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
8/19/2014 12:00 AM Buy
None
31.70 47.00
as of 10/17/2014
1 Week up  0.09 %
1 Month up  7.00 %
3 Months up  0.22 %
1 YTD up  0.22 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy